Stockscreener 앱 받기
39.01
0.10%
-0.04
전일 마감가:
$39.05
열려 있는:
$39.28
하루 거래량:
2.77M
Relative Volume:
0.93
시가총액:
$4.95B
수익:
$638.78M
순이익/손실:
$-22.66M
주가수익비율:
-223.68
EPS:
-0.1744
순현금흐름:
$122.18M
1주 성능:
+9.18%
1개월 성능:
+27.03%
6개월 성능:
+134.72%
1년 성능:
+199.85%
1일 변동 폭
$38.19
$39.83
1주일 범위
$34.57
$40.08
52주 변동 폭
$11.16
$40.08
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
39.01 | 4.87B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
192.74 | 28.83B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
69.03 | 13.69B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
60.27 | 10.40B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
95.31 | 7.55B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
84.05 | 6.42B | 646.34M | -512.40M | 202.76M | -6.6871 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 개시 | Piper Sandler | Neutral |
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
Piper Sandler raises 10X Genomics stock price target on clinical pivot - Investing.com UK
10x Genomics stock hits 52-week high at 37.58 USD - Investing.com
Spatial Genomics and Transcriptomics Market Size to Reach USD 1.90 Billion by 2035, Growing at a 12.23% CAGR | SNS Insider - GlobeNewswire Inc.
10x Genomics, Inc.(NasdaqGS:TXG) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
10x Genomics Inc Class A Actuals & Estimates (FWB:1KJ) - TradingView
1KJ Forecast — Price Target — Prediction for 2027 - TradingView
10x Genomics Inc Class A Actuals & Estimates (DUS:1KJ) - TradingView
Stocks making big moves this week: Qualcomm, Accenture, 10x Genomics, Seagate, and Lattice Semiconductor - Yahoo Finance
Price to earnings forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10x Genomics Inc Class A Actuals & Estimates (MUN:1KJ) - TradingView
Enterprise value to revenue forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (NASDAQ:TXG) - TradingView
Enterprise value to EBIT forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10X Genomics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
10x Genomics Inc Class A Actuals & Estimates (LSE:0A88) - TradingView
Enterprise value to EBITDA forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x Genomics Inc Class A Actuals & Estimates (BIVA:TXG) - TradingView
Price to sales forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
TXG Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of 10x Genomics Inc Class A – LSE:0A88 - TradingView
10x genomics CEO Serge Saxonov sells $1.03m in stock By Investing.com - Investing.com Australia
Form 4 10X Genomics Inc For: 24 June By Investing.com - Investing.com Australia
10x genomics CEO Serge Saxonov sells $1.03m in stock - Investing.com
10x Genomics Insider Sold Shares Worth $1,033,269, According to a Recent SEC Filing - marketscreener.com
10x Genomics (TXG) CEO sells 30,000 shares under 10b5-1 plan - Stock Titan
Why Is 10x Genomics (TXG) Stock Soaring Today - Yahoo Finance
Price to book forward of 10x Genomics, Inc. – NASDAQ:TXG - TradingView
10X Genomics Inc (TXG) Institutional Confidence - TradingKey
10X Genomics stock hits 52-week high at 36.0 USD By Investing.com - Investing.com Australia
10X Genomics stock hits 52-week high at 36.0 USD - Investing.com
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
10x Genomics boosts single cell proteomics with acquisition of Proteintech Genomics - SelectScience
Insider Sell: Shehnaaz Suliman Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades - Stock Titan
TXG - Finviz
10x Genomics Expands Oncology Diagnostics Ambitions Through Cleveland Clinic Collaboration - BioPharma APAC
10X Genomics stock rises on Cleveland Clinic partnership - Investing.com
10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - BioSpace
10x Genomics (TXG) Partners with Cleveland Clinic for Bladder Ca - GuruFocus
10x Genomics and Cleveland Clinic Collaborate to Advance Researc - GuruFocus
10X Genomics (TXG) Stock Surges 4% Following Cleveland Clinic Bladder Cancer Research Agreement - Blockonomi
10x Genomics, Inc and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer - marketscreener.com
10X Genomics stock rises on Cleveland Clinic partnership By Investing.com - Investing.com India
10x Genomics partners with Cleveland Clinic on bladder cancer study By Investing.com - Investing.com Nigeria
10x Genomics partners with Cleveland Clinic on bladder cancer study - Investing.com
10X Genomics Inc (TXG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
10X Genomics Inc (TXG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
10X Genomics Inc (TXG) Valuation: PE, PB & Fair Value Analysis - TradingKey
10X Genomics Inc (TXG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
10x Genomics, Cleveland Clinic study aims to predict bladder cancer treatment response - Stock Titan
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10X 제노믹스 주식 (TXG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SULIMAN SHEHNAAZ | Director |
Jun 16 '26 |
Sale |
32.63 |
5,723 |
186,756 |
31,722 |
9.47%
1.20%
자본화:
|
볼륨(24시간):